ATC code J05
| ATC codes |
|---|
| J Antiinfectives for systemic use |
| J01 Antibacterials for systemic use |
| J02 Antimycotics for systemic use |
| J04 Antimycobacterials |
| J05 Antivirals for systemic use |
| Human only |
| J06 Immune sera and immunoglobulins |
| J07 Vaccines |
| ATCvet only |
| QJ51 Antibacterials for intramammary use |
| QJ54 Antimycobacterials for intramammary use |
|
|
ATC code J05 Antivirals for systemic use is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup J05 is part of the anatomical group J Antiinfectives for systemic use.[4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QJ05.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
J05A Direct acting antiviral drugs
J05AA Thiosemicarbazones
- J05AA01 Metisazone
J05AB Nucleosides and nucleotides excluding reverse transcriptase inhibitors
- J05AB01 Aciclovir
- J05AB02 Idoxuridine
- J05AB03 Vidarabine
- J05AB06 Ganciclovir
- J05AB09 Famciclovir
- J05AB11 Valaciclovir
- J05AB12 Cidofovir
- J05AB13 Penciclovir
- J05AB14 Valganciclovir
- J05AB15 Brivudine
- J05AB16 Remdesivir
- J05AB17 Brincidofovir
J05AC Cyclic amines
- J05AC02 Rimantadine
- J05AC03 Tromantadine
J05AD Phosphonic acid derivatives
- J05AD01 Foscarnet
- J05AD02 Fosfonet
J05AE Protease inhibitors
- J05AE01 Saquinavir
- J05AE02 Indinavir
- J05AE03 Ritonavir
- J05AE04 Nelfinavir
- J05AE05 Amprenavir
- J05AE07 Fosamprenavir
- J05AE08 Atazanavir
- J05AE09 Tipranavir
- J05AE10 Darunavir
J05AF Nucleoside and nucleotide reverse-transcriptase inhibitors
- J05AF01 Zidovudine
- J05AF02 Didanosine
- J05AF03 Zalcitabine
- J05AF04 Stavudine
- J05AF05 Lamivudine
- J05AF06 Abacavir
- J05AF07 Tenofovir disoproxil
- J05AF08 Adefovir dipivoxil
- J05AF09 Emtricitabine
- J05AF10 Entecavir
- J05AF11 Telbivudine
- J05AF12 Clevudine
- J05AF13 Tenofovir alafenamide
J05AG Non-nucleoside reverse-transcriptase inhibitors
- J05AG01 Nevirapine
- J05AG02 Delavirdine
- J05AG03 Efavirenz
- J05AG04 Etravirine
- J05AG05 Rilpivirine
- J05AG06 Doravirine
J05AH Neuraminidase inhibitors
- J05AH01 Zanamivir
- J05AH02 Oseltamivir
- J05AH03 Peramivir
- J05AH04 Laninamivir
J05AJ Integrase inhibitors
- J05AJ01 Raltegravir
- J05AJ02 Elvitegravir
- J05AJ03 Dolutegravir
- J05AJ04 Cabotegravir
J05AP Antivirals for treatment of HCV infections
- J05AP01 Ribavirin
- J05AP02 Telaprevir
- J05AP03 Boceprevir
- J05AP04 Faldaprevir
- J05AP05 Simeprevir
- J05AP06 Asunaprevir
- J05AP07 Daclatasvir
- J05AP08 Sofosbuvir
- J05AP09 Dasabuvir
- J05AP10 Elbasvir
- J05AP11 Grazoprevir
- J05AP12 Coblopasvir
- J05AP51 Sofosbuvir and ledipasvir
- J05AP52 Dasabuvir, ombitasvir, paritaprevir and ritonavir
- J05AP53 Ombitasvir, paritaprevir and ritonavir
- J05AP54 Elbasvir and grazoprevir
- J05AP55 Sofosbuvir and velpatasvir
- J05AP56 Sofosbuvir, velpatasvir and voxilaprevir
- J05AP57 Glecaprevir and pibrentasvir
- J05AP58 Daclatasvir, asunaprevir and beclabuvir
J05AR Antivirals for treatment of HIV infections, combinations
- J05AR01 Zidovudine and lamivudine
- J05AR02 Lamivudine and abacavir
- J05AR03 Tenofovir disoproxil and emtricitabine
- J05AR04 Zidovudine, lamivudine and abacavir
- J05AR05 Zidovudine, lamivudine and nevirapine
- J05AR06 Emtricitabine, tenofovir disoproxil and efavirenz
- J05AR07 Stavudine, lamivudine and nevirapine
- J05AR08 Emtricitabine, tenofovir disoproxil and rilpivirine
- J05AR09 Emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat
- J05AR10 Lopinavir and ritonavir
- J05AR11 Lamivudine, tenofovir disoproxil and efavirenz
- J05AR12 Lamivudine and tenofovir disoproxil
- J05AR13 Lamivudine, abacavir and dolutegravir
- J05AR14 Darunavir and cobicistat
- J05AR15 Atazanavir and cobicistat
- J05AR16 Lamivudine and raltegravir
- J05AR17 Emtricitabine and tenofovir alafenamide
- J05AR18 Emtricitabine, tenofovir alafenamide, elvitegravir and cobicistat
- J05AR19 Emtricitabine, tenofovir alafenamide and rilpivirine
- J05AR20 Emtricitabine, tenofovir alafenamide and bictegravir
- J05AR21 Dolutegravir and rilpivirine
- J05AR22 Emtricitabine, tenofovir alafenamide, darunavir and cobicistat
- J05AR23 Atazanavir and ritonavir
- J05AR24 Lamivudine, tenofovir disoproxil and doravirine
- J05AR25 Lamivudine and dolutegravir
- J05AR26 Darunavir and ritonavir
- J05AR27 Lamivudine, tenofovir disoproxil and dolutegravir
J05AX Other antivirals
- J05AX01 Moroxydine
- J05AX02 Lysozyme
- J05AX05 Inosine pranobex
- J05AX06 Pleconaril
- J05AX07 Enfuvirtide
- J05AX09 Maraviroc
- J05AX10 Maribavir
- J05AX12 Dolutegravir
- J05AX13 Umifenovir
- J05AX17 Enisamium iodide
- J05AX18 Letermovir
- J05AX19 Tilorone
- J05AX21 Pentanedioic acid imidazolyl ethanamide
- J05AX23 Ibalizumab
- J05AX24 Tecovirimat
- J05AX25 Baloxavir marboxil
- J05AX26 Amenamevir
- J05AX27 Favipiravir
- J05AX28 Bulevirtide
- J05AX29 Fostemsavir
- J05AX31 Lenacapavir
References
- ↑ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ↑ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ↑ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ↑ "ATC/DDD Index 2022: code J05". WHO Collaborating Centre for Drug Statistics Methodology.
- ↑ "ATCvet Index 2022: code QJ05". WHO Collaborating Centre for Drug Statistics Methodology.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.